The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.

Related Articles

The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.

Annu Rev Med. 2017 Jan 14;68:153-168

Authors: Ernani V, Steuer CE, Jahanzeb M

Abstract
Lung cancer is the leading cause of cancer death in the United States and many other parts of the world. Non-small cell lung cancer (NSCLC) comprises 85-90% of lung cancers. Historically, the expected survival of patients with advanced disease has been estimated in months. In recent years, however, lung cancer has come to be seen as a treatable disease with multiple therapeutic options. Enormous advances in the understanding of its pathways and mechanisms have enabled personalized therapy in NSCLC. The evolving approach to therapy focuses on genomic profiling of the tumors to find molecular targets and develop specific agents for individualized therapy. In addition, maintenance therapy has emerged as a valid approach, and the choice of chemotherapy now varies by histology. Most recently, immunotherapy with checkpoint inhibitors has shown promising results, with impressive durations of response and a tolerable toxicity profile. Together, these discoveries have improved overall survival substantially in patient populations that have access to these advancements. We review the clinical data surrounding these impressive improvements.

PMID: 27618751 [PubMed - indexed for MEDLINE]

http://ift.tt/2EC4Wor